For example, ZSTK474 inhibitor displayed a potent anticancer activity in human tumor xenografts [47] while BYL719 has shown synergistic antineoplastic efficacy when used in endocrine cure against ER+/PIK3CA mutated breast tumor cells [48]. The gene discussed is PIK3CA; the disease is breast neoplasm.